Abstract
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5401-5411 |
| Number of pages | 11 |
| Journal | Blood |
| Volume | 113 |
| Issue number | 22 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology
Cite this
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia : The ADAGIO study. / Noens, Lucien; Van Lierde, Marie Anne; De Bock, Robrecht; Verhoef, Gregor; Zachée, Pierre; Berneman, Zwi; Martiat, Philippe; Mineur, Philippe; Van Eygen, Koen; MacDonald, Karen; De Geest, Sabina; Albrecht, Tara; Abraham, Ivo L.
In: Blood, Vol. 113, No. 22, 2009, p. 5401-5411.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia
T2 - The ADAGIO study
AU - Noens, Lucien
AU - Van Lierde, Marie Anne
AU - De Bock, Robrecht
AU - Verhoef, Gregor
AU - Zachée, Pierre
AU - Berneman, Zwi
AU - Martiat, Philippe
AU - Mineur, Philippe
AU - Van Eygen, Koen
AU - MacDonald, Karen
AU - De Geest, Sabina
AU - Albrecht, Tara
AU - Abraham, Ivo L
PY - 2009
Y1 - 2009
N2 - Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.
AB - Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.
UR - http://www.scopus.com/inward/record.url?scp=67049087117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67049087117&partnerID=8YFLogxK
U2 - 10.1182/blood-2008-12-196543
DO - 10.1182/blood-2008-12-196543
M3 - Article
C2 - 19349618
AN - SCOPUS:67049087117
VL - 113
SP - 5401
EP - 5411
JO - Blood
JF - Blood
SN - 0006-4971
IS - 22
ER -